ELISA News and Research

RSS

Seroprevalence study reveals high exposure to SARS-CoV-2 in Bangui population

Researchers performed a cross-sectional study in the city of Bangui, the capital of the Central African Republic from July 12, 2021, to August 20, 2021.

28 Nov 2021

Study explores adverse effects of SARS-CoV-2-induced antibody responses

The authors of a research paper published in the journal Frontiers in Immunology used Sandwich ELISA tests to determine the distribution of IgG sub-classes and complement activation levels in plasma from convalescent individuals.

25 Nov 2021

Serum SARS-CoV-2 antigen: A better predictor of COVID-19 severity

In this perspective, a new study published on the medRxiv* preprint server analyzed the clinical efficacy of two serum antigen tests to identify SARS CoV-2 infection and evaluate the kinetics of serum nucleocapsid (N) antigen in severe and non-severe patients for disease severity prediction.

24 Nov 2021

Acute SARS-CoV-2 infection during pregnancy associated with placental ACE2 shedding

A new study, published on the bioRxiv* preprint server, hypothesized that ACE-2 expression and ADAM17 activity in the placenta is affected by the timing of SARS-CoV-2 infection of the mother.

24 Nov 2021

Similar antibody responses to spike protein in COVID-19 survivors and vaccine recipients

Researchers conducted a study on COVID-19 convalescent patients and post-vaccinated populations to identify the minimal levels of antibody required to protect against SARS-CoV-2 infection.

24 Nov 2021

Limited immune responses three months after Pfizer-BioNTech vaccination among elderly

In this study, published on the medRxiv* preprint server, the humoral response to SARS-CoV-2 was assessed before and after three months of administration of the BNT162b2 mRNA COVID-19 vaccination (Pfizer-BioNTech). In addition, elders' humoral responses were compared to those of a younger group, and a functional neutralization experiment against the Wuhan-Hu-1 (WH1) virus and the Delta variant was carried out.

23 Nov 2021

Antigenic cocktail produced in Nicotiana benthamian plant as a potential COVID-19 vaccine candidate

Scientists utilize N. benthamiana for producing the N-protein and an antigenic cocktail containing the N-protein and SARS-CoV-2 S RBD.

23 Nov 2021

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

Scientists generate a VLP type NP platform made of recombinant viral antigens conjugated with TMV virions.

23 Nov 2021

WHO’s C-TAP and MPP finalize licensing agreement with CSIC for COVID-19 serological antibody technology

WHO's COVID-19 Technology Access Pool and the Medicines Patent Pool today finalized a licensing agreement with the Spanish National Research Council for a COVID-19 serological antibody technology.

23 Nov 2021

How the new In-Vitro Diagnostics Regulations are affecting the life sciences landscape

In this interview, News-Medical talks to Laura Nea, Vice President of Quality and Regulatory Management at Tecan, about the upcoming changes to the regulations surrounding in-vitro diagnostics and how they might affect the life sciences landscape.

From Tecan 23 Nov 2021

Preexisting rhinovirus infection and IFN induction in epithelium of asthma patients decreases SARS-CoV-2 infection

In a recent study, researchers explored the effects of RV, HDM, and SARS-CoV-2 on differentiated primary human bronchial epithelial cells (HBECs) in vitro and in experimental in vivo RV infection in healthy subjects and asthmatic patients.

22 Nov 2021

Researchers make progress towards a new diagnostic test for schistosomiasis

Researchers have made important progress towards a new diagnostic test for schistosomiasis, which could help the World Health Organization achieve its goal of interrupting transmission of the disease, and eventually eliminating it.

22 Nov 2021

Paper-based innovations for COVID-19 diagnosis

A review discusses paper-based devices and platforms targeting SARS-CoV-2 for low-cost PoC diagnosis and serological antibody testing.

22 Nov 2021

Detection of SARS-CoV-2 spike antibody using electrochemical biosensing based on hydrogen bonding

Turkish researchers discuss their rapid electrochemical biosensing platform to detect the SARS-CoV-2 spike antibody.

22 Nov 2021

Importance of cross-neutralizing antibodies against SARS-CoV-2 variants

A new study published in the journal mBio investigates different antibodies from convalescent donors that bind three separate domains of the SARS-CoV-2 spike. The results of this study suggest that the individuals exposed to the SARS-CoV-2 from the first wave have neutralizing antibodies against current variants.

21 Nov 2021

Sheep at low-risk for infection with SARS-CoV-2

A team of scientists from the US has recently evaluated the susceptibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in sheep. The findings reveal that sheep are generally less susceptible to SARS-CoV-2 infection. However, the susceptibility is relatively higher for the alpha variant of the virus. The study is currently available on the bioRxiv preprint server.

21 Nov 2021

How to achieve fast, accurate and reliable quantitation of AAV serotypes

In this interview, News-Medical talks to Indrani Chakraborty from GatorBio about how they have achieved accurate and reliable quantitation of AAV serotypes.

From Gator Bio, Inc. 19 Nov 2021

A nasal COVID vaccine using a weakened influenza vector

The authors of a new study, published on the bioRxiv* preprint server, constructed a COVID-19 nasal vaccine candidate by inserting a gene encoding the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2, named CA4-dNS1-nCoV-RBD (dNS1-RBD) in a live attenuated influenza virus (LAIV) vector.

18 Nov 2021

Novel strategy to produce SARS-CoV-2 nucleocapsid protein for serological testing

New research discusses an alternative method of purifying the SARS-CoV-2 N protein using only metal exchange chromatography and denaturing conditions.

18 Nov 2021

Study shows neutralizing capacity of monoclonal antibodies against SARS-CoV-2 variants of concern

Canadian public health researchers recently published a study in the journal Antiviral Research wherein they described generating a panel of murine hybridomas recognizing SARS-CoV-2 spike protein or nucleoprotein, capable of neutralizing the SARS-CoV-2 variants of concern, proving their therapeutic potential.

17 Nov 2021

ELISA News and Research

Seroprevalence study reveals high exposure to SARS-CoV-2 in Bangui population

Study explores adverse effects of SARS-CoV-2-induced antibody responses

Serum SARS-CoV-2 antigen: A better predictor of COVID-19 severity

Acute SARS-CoV-2 infection during pregnancy associated with placental ACE2 shedding

Similar antibody responses to spike protein in COVID-19 survivors and vaccine recipients

Limited immune responses three months after Pfizer-BioNTech vaccination among elderly

Antigenic cocktail produced in Nicotiana benthamian plant as a potential COVID-19 vaccine candidate

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

WHO’s C-TAP and MPP finalize licensing agreement with CSIC for COVID-19 serological antibody technology

How the new In-Vitro Diagnostics Regulations are affecting the life sciences landscape

Preexisting rhinovirus infection and IFN induction in epithelium of asthma patients decreases SARS-CoV-2 infection

Researchers make progress towards a new diagnostic test for schistosomiasis

Paper-based innovations for COVID-19 diagnosis

Detection of SARS-CoV-2 spike antibody using electrochemical biosensing based on hydrogen bonding

Importance of cross-neutralizing antibodies against SARS-CoV-2 variants

Sheep at low-risk for infection with SARS-CoV-2

How to achieve fast, accurate and reliable quantitation of AAV serotypes

A nasal COVID vaccine using a weakened influenza vector

Novel strategy to produce SARS-CoV-2 nucleocapsid protein for serological testing

Study shows neutralizing capacity of monoclonal antibodies against SARS-CoV-2 variants of concern

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News